NCT00090233View on ClinicalTrials.gov

Rotavirus Efficacy and Safety Trial (REST)(V260-006)

PHASE3CompletedINTERVENTIONAL
Enrollment

69,274

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions
Rotavirus Infections
Interventions
BIOLOGICAL

Rotateq™

3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.

BIOLOGICAL

Comparator: Placebo

3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00090233 - Rotavirus Efficacy and Safety Trial (REST)(V260-006) | Biotech Hunter | Biotech Hunter